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Abstract
Background: In malaria-endemic countries, malaria prevention and treatment are critical for child health. In the
context of intervention scale-up and rapid changes in endemicity, projections of intervention impact and optimized
program scale-up strategies need to take into account the consequent dynamics of transmission and immunity.
Methods: The new Spectrum-Malaria program planning tool was used to project health impacts of Insecticide-Treated
mosquito Nets (ITNs) and effective management of uncomplicated malaria cases (CMU), among other interventions,
on malaria infection prevalence, case incidence and mortality in children 0–4 years, 5–14 years of age and adults.
Spectrum-Malaria uses statistical models fitted to simulations of the dynamic effects of increasing intervention
coverage on these burdens as a function of baseline malaria endemicity, seasonality in transmission and malaria
intervention coverage levels (estimated for years 2000 to 2015 by the World Health Organization and Malaria Atlas
Project). Spectrum-Malaria projections of proportional reductions in under-five malaria mortality were compared with
those of the Lives Saved Tool (LiST) for the Democratic Republic of the Congo and Zambia, for given (standardized)
scenarios of ITN and/or CMU scale-up over 2016–2030.
Results: Proportional mortality reductions over the first two years following scale-up of ITNs from near-zero baselines
to moderately higher coverages align well between LiST and Spectrum-Malaria —as expected since both models were
fitted to cluster-randomized ITN trials in moderate-to-high-endemic settings with 2-year durations. For further scale-up
from moderately high ITN coverage to near-universal coverage (as currently relevant for strategic planning for many
countries), Spectrum-Malaria predicts smaller additional ITN impacts than LiST, reflecting progressive saturation. For
CMU, especially in the longer term (over 2022–2030) and for lower-endemic settings (like Zambia), Spectrum-Malaria
projects larger proportional impacts, reflecting onward dynamic effects not fully captured by LiST.
Conclusions: Spectrum-Malaria complements LiST by extending the scope of malaria interventions, program packages
and health outcomes that can be evaluated for policy making and strategic planning within and beyond the
perspective of child survival.
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Background
In malaria-endemic countries, malaria prevention and
treatment are critical for child health. Between 2000 and
2015, malaria incidence rates fell 37% globally, and mal-
aria mortality rates by 60%, with even greater declines in
Africa, the highest-burden region [1]. This was likely a
combined result of improved malaria control and other
factors independent of interventions [2]. Across all age
groups in sub-Saharan Africa, malaria control interven-
tions accounted for an estimated 70% of the 943 million
fewer malaria cases occurring between 2001 and 2015.
For malaria deaths in children under-5, in 2012 the
World Health Organization (WHO) had estimated that
malaria prevention intervention scale-up over 2001–
2010 had prevented 921,300 (uncertainty interval:
625,600–1,260,800) child deaths (or 8.2% of the number
in 2000) due to malaria across 36 malaria-endemic
countries in Africa [3]. Impacts of improved case man-
agement, as well as mortality and morbidity impacts in
older children and adults, are less certain.
As funding for malaria control has now plateaued, it is
even more critical than before to prioritize interventions
with the most impact, and determine and plan the opti-
mal mix of interventions for each setting and time
period —within the broader public health and health
sector context. We developed a malaria strategic plan-
ning module in the Spectrum suite of policy models, to
complement similar modules included for HIV/AIDS,
tuberculosis and family planning, which are used by over
120 low and middle-income countries for estimation of
burdens, trends, service needs and program impact [4–7].
The Spectrum-Malaria module extends the malaria im-
pact modelling options available through the Lives Saved
Tool (LiST) [3, 8, 9], by projecting impacts on not only
mortality but also morbidity (malaria case incidence and
prevalence of infection with Plasmodium falciparum
(PfPR), for not only children 0–4 years but also children
5–14 years and adults. Besides Insecticide-Treated mos-
quito Nets (ITNs), Indoor Residual Spraying (IRS) and
first-line treatment of malaria cases, also modelled in LiST,
Spectrum-Malaria additionally projects the impact of se-
vere case management of sever malaria cases, and sea-
sonal malaria chemoprophylaxis for young children.
Additional long-awaited refinements [10, 11] are the rep-
resentation of dynamic effects of transmission and im-
munity over time and variation in impacts depending on
baseline endemicity, intervention coverage levels —based
on statistical summaries of simulations [12–14] performed
in the dynamic model OpenMalaria [15, 16].
This article presents and compares projections of the
impact on under-five mortality of ITNs and effective
malaria case management, performed in Spectrum-
Malaria and in LiST, for a high-endemic and a low-
endemic African setting. Differences and similarities are
discussed with implications for interpreting modelling
results for strategic planning. Options are discussed for
updating and aligning both models and their input data
and assumptions, and for operating both models in com-
bination to cover the fullest set of interventions relevant
for comprehensive program planning.
Methods
Projections were made for the Democratic Republic of
the Congo (DRC), as an example of a setting with stable
high endemicity, and Zambia as an example of a setting
with lower endemicity, over a 15-year horizon, and
under-5 mortality impacts were compared between LiST
and Spectrum-Malaria.
Spectrum-Malaria projections
The Spectrum-Malaria model of 15th June 2016 (version
5.45 Beta 4) was used, detailed elsewhere [12, 14]. This
includes statistical regression models that predict the
proportional reduction in PfPR, case incidence and mal-
aria mortality, for a given change in intervention cover-
age, fitted to simulations of such intervention scenarios
in the dynamic transmission model OpenMalaria [13].
Spectrum thus provides a simple, quick calculation tool
for program planners that captures most of the dynam-
ics of the full OpenMalaria research model. Interven-
tions included were: ITNs, IRS, effective management of
uncomplicated malaria cases (CMU) and of severe cases,
and seasonal malaria chemoprophylaxis for children 3–
59 months.
For simulations underlying Spectrum’s statistical esti-
mates of ITN impacts, the effectiveness of ITNs (and IRS)
in the OpenMalaria model had been calibrated [13] to fit
the observed 2-year impacts on under-five mortality, case
incidence and parasite infection prevalence from three
ITN trials in Kenya and Ghana [17], that were also the
basis for mortality effectiveness assumptions in LiST [9].
Effectiveness of management of uncomplicated malaria
cases was modeled assuming a 100% cure rate for malaria
patients complying with an effective antimalarial treat-
ment, e.g. with an artemisinin-based combination therapy
(ACT) [18].
Malaria mortality rates at 2014 and 2015 (and preceding
years) were taken from the WHO’s official national
estimates of November 2015 [1] for children under-5 ver-
sus older age groups. Baseline (2000–2015) data for the
impact modifiers, seasonality in malaria transmission, and
PfPR in children 2–9 years, were taken from estimates by
the Malaria Atlas Project [2, 19] —aggregated from 5 × 5
km2 pixel level estimates into first administrative level
(Admin1) units (i.e. states or provinces). National-level
impacts are computed by Spectrum-Malaria by
aggregating burden and impact projections for each prov-
ince in a country, thus taking account of (part of the) sub-
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national variation in impact determinants. The WHO’s
national-level mortality estimates were distributed over
Admin1 units by assuming a similar proportional distribu-
tion as estimated by the Malaria Atlas Project for malaria
case incidence [2, 19].
For projections over 2016–2030, Spectrum applied
proportional impacts predicted by regression models fit-
ted to the average outcomes over years 1–3 after inter-
vention scale-up from OpenMalaria simulations [13]
over 2016–2021; for 2022–2030 Spectrum applied the
proportional impacts from regression models fitted to
average OpenMalaria simulation outcomes over years 8–
10 after scale-up [13]. Spectrum applies these impact
functions with a one-year time lag from intervention
scale-up to start of impact, thus the projected burdens
in 2016 reflected the effect of intervention coverage
changes from 2014 to 2015, and onwards (Table 1).
LiST projections
LiST was used in the version ‘Spectrum 5.43 beta 1’ of
May 2016. Outputs analyzed were the cause-specific deaths
in children under five years (i.e. 0–59 months) of age. All-
cause neonatal and post-neonatal mortality rates at 2014
and 2015 (and preceding years) were taken from estimates
by the United Nations Inter-Agency Group for Child Mor-
tality Estimation as of 2015 [20] (Table 2). The correspond-
ing malaria mortality rates were derived by applying the
proportion of post-neonatal under-5 deaths due to malaria
(among eight other causes) from the WHO in the version
as of October 2015 (http://www.who.int/healthinfo/
global_burden_disease/estimates/en/index3.html) and [1].
Effectiveness of ITNs and/or IRS (with the coverage
definitions detailed in Table 3), was estimated and im-
plemented as children 1–59 months living in households
protected by ITNs and/or IRS having a 55% lower risk
of malaria-attributable death [9]. Treatment of Plasmo-
dium falciparum malaria cases (without distinction be-
tween uncomplicated and severe cases) with artemisinin
combination therapy (ACT) was assumed to reduce mal-
aria mortality in children 1–23 months by 99% (range:
94–100%), and in children 24–59 months by 97% (range:
86–99%) [21].
Standardized intervention scale-up and scale-down
scenarios
For the current model comparisons, baseline coverages
and intervention scale-up targets for ITNs and CMU
were standardized between LiST and Spectrum-Malaria
(Table 3, row labeled ‘Coverage-standardized, DRC &
Zambia’), and between the two countries, so as have a
similar extent of scale-up from baseline to target level in
both countries. Coverage values were set in the range of
default coverage values assumed by the two models for
the two countries, as explained in the following two
paragraphs and with precise annual values shown in
Additional file 1.
For vector control, LiST uses a combined coverage
metric combining protection by ITNs and/or IRS, de-
fined as the proportion of children under-5 who live in a
household owning one or more ITNs, and/or in a house
that has been sprayed with IRS within the past
12 months. Spectrum-Malaria uses as coverage metrics:
for ITNs, the proportion of the population of all ages
who slept under an ITN the last night; and for IRS, the
proportion of the population of all ages who live in a
house sprayed with IRS within the past 12 months. The
standardized coverage assumptions we used for projec-
tions and comparisons were: for LiST, 70% ITN/IRS pro-
tection at 2014 and 2015 (close to the LiST default
values of 70% for DRC and 74.7% for Zambia), in-
creasing to 98% as the maximum target level (at 2016,
or at 2020 with linear increase over 2016–2020); for
Spectrum-Malaria, the standardized coverage assump-
tion (judged most similar to standardized coverage in
LiST) was 51% ITN usage at 2014 and 2015 (slightly
below the Spectrum-Malaria default values of 55% for
DRC and 68.8% for Zambia), increasing to 70% as max-
imum target level. We considered 51% and 70% usage to
be similar to 77% and 98% of households owning one or
more ITNs, based on ratios between these metrics in
DRC, Zambia and other stable malaria-endemic African
countries observed in national household surveys ([22–
24] and Additional file 2), and therefore we consider these
standardized coverage values optimal for the purpose of
comparing impact projections despite the different cover-
age metrics in the two models. In Spectrum-Malaria, IRS
coverage was kept constant throughout 2014–2030, so
that IRS coverage did not have any projected impact.
For malaria case management, Spectrum-Malaria dis-
tinguishes between uncomplicated cases and severe
cases, but LiST does not. We compared management of
uncomplicated cases from Spectrum-Malaria with over-
all case management from LIST. For these respective in-
terventions, both models use as input the coverage of
child fevers treated with an ACT, as observed in national
household surveys: most often, Demographic and Health
Surveys (DHS) [25], Multiple Indicator Cluster Surveys
(MICS) [26] and Malaria Indicator Surveys (MIS) [27].
LiST inputs new survey data points individually and
continually as these survey data are released, while
Spectrum-Malaria pre-loaded a multi-country dataset of
survey-based coverage estimates for 2005, 2010 and
2015, in which survey data were adjusted and extrapolated
in a standardized way to years and countries without
surveys [28]. In Spectrum-Malaria for most African
countries including DRC and Zambia, less than 8% of
cases are severe [12, 14], so the difference in denominators
(uncomplicated cases versus all malaria cases) should not
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invalidate the comparison of their impacts. For the current
projections, coverage in both DRC and Zambia was set at
10% for 2014 and 2015, increasing to 40% as maximum
target level (again reached either in 2016, or in alternative
scenarios by 2020 with linear scale-up over 2016–2020).
Using these target coverage levels for ITNs and
CMU, we modelled and compared the following 6
scale-up scenarios:
 Scaling-up ITN to the stated target coverage;
 Scaling-up CMU to the stated target coverage;
 Scaling-up ITNs and CMU to the stated respective
target coverages, in parallel; with for each of these
3 intervention targets: either scale-up at once
realized in 2016 and maintained throughout 2030, or
a linear scale-up starting in 2016 with the target
coverage level reached by 2020 and then maintained
until 2030.
In addition, to show the coverage-to-impact relation-
ship over a wide coverage range, including the effect of
scaling-down coverage to below the 2014–2015 baseline
Table 1 Key structural and methodological differences between LiST and Spectrum-Malaria
Aspect LiST Spectrum-Malaria
Health outcomes considered, that are
impacted by malaria interventions
• Malaria-attributable, other-cause and
all-cause mortality in children 0–4 years
(separately for neonatal, 1–12 months and
13–59 months sub-groups)
• Maternal deaths
• Stillbirths
• Malaria-attributable mortality and case
incidence, in 0–4 years, 5–14 years and
15+ years;
• Plasmodium falciparum infection
prevalence (PfPR), in children 2–9 years
Interventions modelled • Vector control (IRS and/or ITNs)
• Case management, uncomplicated malaria
cases
• Intermittent Preventive Therapy for
pregnant women
• ITNs
• IRS
• Case management, uncomplicated malaria
cases (CMU)
• Case management, severe malaria cases
• Seasonal Malaria Chemoprophylaxis (SMC)
in children 3–59 months
Determinants of impact of malaria
intervention scale-up
Proportional reduction from baseline burden
level, for a given proportional increase in
intervention coverage – same within and
across all countries
Proportional reduction from baseline burden
level, varying with baseline endemicity
(PfPR), seasonality in malaria transmission,
and baseline and scale-up coverage levels of
ITNs, IRS, CMU and SMC, which act in
interaction), calculated at province-level and
then aggregated to national level [13]
Determinants of impact, for a given
coverage increase
Fixed effectiveness value (for ITNs and CMU:
from sources below), for all years and all
countries [48]
• Baseline malaria endemicity (PfPR in
2–9 years),
• Seasonality in malaria transmission,
• Baseline and scale-up coverage levels of
other malaria interventions that have
time-dynamic impacts (ITNs, IRS, SMC, and
management of uncomplicated cases), and
their variations between provinces, within
and across countries [13].
Synergy or saturation across interventions? No Yes [13].
Saturation of incremental impacts at higher
coverages?
No Yes [13].
Time path of impact No variation over time: impact is immediate
from the year of scale-up; the post-intervention
mortality level stays constant thereafter until
coverage changes again
• Impact modelled with a 1-year lag after
intervention scale-up;
• Separate impact functions for short term
(years 2–6 after scale-up) and long term
(years 7–15 after scale-up) [12, 14].
Basis and source of coverage-impact
relationship: ITNs
United Nationals Child Health Epidemiology
Reference Group (CHERG), meta-analysis of
randomized ITN trials [9]
Dynamic transmission model simulations for
a wide range of sub-Sahara-Africa like
scenarios, varying in endemicity, seasonality
and baseline intervention coverages,
performed in the OpenMalaria model –
summarized in multi-variate statistical
models [13]. OpenMalaria intervention
effectiveness assumptions were in turn
based on meta-analysis of randomized ITN
trials [9], and review of observational
treatment impact studies [18, 49]
Basis and source of coverage-impact
relationship: case management
Meta-analyses of published observational
studies and a previous Delphi estimate [21]
Differences in data sources, intervention coverage definitions and country baseline parameter values are described in Tables 1 and 2
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level, several scale-down scenarios were modelled (de-
tails in Additional file 1), with each coverage change im-
plemented at once in 2016 and sustained until 2030.
Health outcomes and time horizons evaluated
Impacts were compared as proportional reductions in
under-5 mortality numbers, so that some small differ-
ences in baseline mortality rates between the two models
(Table 2) did not affect the comparison.
We evaluated mortality impacts over 2016–2030, the
horizon considered in Spectrum-Malaria (while LiST
does not specify a specific horizon of validity). Some
comparisons focused on either 2020 or 2025, as indica-
tive of shorter-term impacts versus longer-term impacts,
respectively, being modelled through distinct statistical
impact functions in Spectrum-Malaria [13].
Results
Scaling-up ITN and CMU from 2015 coverage levels
In both LiST and Spectrum-Malaria, increasing CMU
coverage from 10% to 40% has larger impact than in-
creasing ITN coverage from 77% ownership or 51%
usage to 98% ownership or 70% usage (Figure 1).
In LiST, intervention scale-up reduces mortality to a
new post-intervention level within the same year as the
increased intervention coverage; this new mortality rate
is maintained over next years and annual numbers of
deaths reflect this rate multiplied by the (growing) popu-
lation size. In Spectrum-Malaria, intervention scale-up
starting in 2016 results in a reduced mortality rate over
2017–2021, with a further reduced mortality rate over
2022–2030 reflecting the long-term transmission dy-
namic effect. For ITNs, proportional under-5 mortality
reductions following scale-up are somewhat larger in
LiST than in Spectrum-Malaria, for both DRC and
Zambia in the short-term over 2016–2021 (Fig. 2, left).
Over 2022–2030, proportional ITN impacts are similar
between both models for Zambia, but still larger in LiST
for DRC (Fig. 2, right).
For CMU, in contrast, Spectrum-Malaria predicts larger
proportional mortality reductions than LiST, for both
countries, across 2016–2030 and throughout the coverage
range of 0–100%, but especially so for lower-endemic
Zambia and for the longer (2022–2030) time horizon.
For both interventions, LiST projects identical propor-
tional impacts for a given coverage increase in DRC and
Zambia (Fig. 2 & Table 4), and across all other countries
(not shown). Spectrum-Malaria, in contrast, projects lar-
ger proportional burden reductions for the lower-
endemic Zambia, compared to the higher-endemic DRC.
Scaling-down ITN and CMU from 2015 coverage levels
For scenarios decreasing ITN coverage to below the
2015 actual coverages (which were already high in both
Table 2 Parameters and input data used by LiST and Spectrum-Malaria in projections for DRC and Zambia
Parameter (2015, unless
otherwise indicated)
DRC Zambia Data sources & definitions
Spectrum-Malaria LiST Spectrum-Malaria LiST Spectrum-Malaria LiST
Population at malaria riska 97.1% 91% 100% 98% All-age population living where PfPR among
2–9 years >0 [2, 19]
Women exposed
to P. falciparum
malaria [50]
Population 0–4 years (including
children living not at
malaria risk)
12,373,927 13,682,392 2,848,069 2,888,817 United Nations Population Division [51]
Index for seasonality in malaria
transmission
0.36 NA 1.64 NA Coefficient of variation in EIR over a year,
defined as the standard deviation divided
by the year-average of monthly EIR [34];
country estimates from Malaria Atlas
Project [2, 19]
Prevalence of P. falciparum
infection in children 2–9 years,
average over 2000–2002
64% NA 35% NA Malaria Atlas Project [19]
Malaria deaths in children
0–59 months (% of all-cause
deaths)
33,038 47,473 (16%) 2734 2723 (5.9%) WHO (http://www.who.int/healthinfo/
global_burden_disease/estimates/en/
index3.html and [1])
WHO
All-cause under-5 deaths NA 298,200 NA 45,916 NA UN Inter-Agency
Group for Child
Mortality Estimation [20]
Malaria deaths in 5–14 years 3258 NA 2226 NA WHO [1]; share of 5–14 versus 15+ years as
for malaria cases [2, 19]
NA
Malaria deaths in 15+ years 2936 NA 2074 NA
Malaria cases i.e. disease episodes
in 0–4 years
8,231,156 NA 1,188,935 NA WHO [1]; the share of 0–4 years in WHO’s
all age estimate taken from Malaria Atlas
Project [2, 19]
NA
Abbreviations: EIR Entomological Inoculation Rate, LiST Lives Saved Tool, DRC Democratic Republic of the Congo, MAP Malaria Atlas Project, P. falciparum Plasmodium
falciparum, NA not available
aThe population at risk of malaria does not influence impact calculations, but it is used in the OneHealth Tool costing as the ‘Population in Need’ (PIN) that would need
to get various services like ITNs, IRS spraying, etc. (Equation for number of services: Target Population * PIN * Coverage)
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DRC and Zambia, and in our coverage-standardized var-
iants of these countries), Spectrum-Malaria predicts a
similar mortality increase as LiST for DRC over the first
five years after ITN scale-down (represented as a drop
from 51% to 12.5% utilization, or from 77% to 18% own-
ership), followed by a further mortality rise compared to
LiST from the 7th year following scale-down (Fig. 3). For
Zambia, in the short-term (over 2016–2021) and espe-
cially the longer-term (over 2022–2030), the projected
mortality rise due to ITN coverage decrease is larger in
Spectrum-Malaria than in LiST.
Non-linearity in the coverage-impact relationship
We compared mortality impacts for a given coverage in-
crease or decrease, over the full 0–100% range of possible
coverages and between the countries, as comparative pro-
portional mortality reductions relative to the mortality
level under a constant-coverage scenario, at the year 2020.
In LiST, the effect of a given coverage increase is calcu-
lated as a simple multiplication of (reduced) relative risks
that are linear with the coverage increase, identically for
all countries, as shown in Fig. 4, with identical lines for
DRC and Zambia. Spectrum-Malaria, in contrast, shows
larger proportional impacts of both ITN and CMU for the
lower-endemic Zambia (steeper curves in Figs. 4b and d)
than for higher-endemic DRC. Spectrum-Malaria further-
more shows an important saturation effect apparent at
coverage levels of around 50% or higher, for both inter-
ventions: adding 20 percentage points ITN or CMU
coverage from a moderately high baseline level of e.g. 50%
coverage does not produce as large a mortality reduction
as adding 20 percentage point coverage from a low base-
line level of e.g. 10%.
Interaction between ITNs and CMU
A non-linearity that is captured in Spectrum-Malaria
but not in LiST is interaction between interventions, for
example between ITNs and CMU. In LiST, the propor-
tional impacts of concurrent ITN/IRS and CMU scale-
up equate the product of the proportional impacts of the
two interventions when implemented each in isolation
(Table 4). In Spectrum-Malaria, in contrast, for both
DRC and Zambia, concurrent scale-up to high coverage
levels for ITNs and CMU simultaneously entails a slight
saturation in the overall impact, with the overall propor-
tional reduction slightly less than the product of the cor-
responding relative reductions achieved by the two
interventions when each applied alone.
Table 3 Intervention coverage at 2015 in DRC and Zambia, and two coverage-standardized country variants modelled
Module ITN coverage IRS coverage Malaria case management
DRC Spectrum-
Malaria
Usage: 55% 0.27% 6.6%
LiST ITN owning and/or IRS-sprayed: 70% 1.7%
Zambia Spectrum-
Malaria
Usage: 68.8% 35.6% 44.1%
LiST ITN owning and/or IRS-sprayed: 74.7% 18.4%
Coverage-
standardized,
DRC & Zambiab
Spectrum-
Malaria
• 51% ITN usage at 2014 & 2015;
• 70% ITN usage as target for 2016–2020;
• IRS: 0.28% throughout 2014–2030.
• 10% at 2014 & 2015;
• 40% as target for 2016–2020
LiST • 77% ITN owning and/or IRS sprayed
at 2014 & 2015;
• 98% as target for 2016–2020
• 10% at 2014 & 2015;
• 40% as target for 2016–2020.
Data source &
definition
Spectrum-
Malaria
WHO/MAP 2015 [24], % of national
population sleeping under an ITN
(including areas with PfPR = 0).
WHO 2015 [1], % of national
population protected (all ages,
including areas with PfPR = 0)
ACT treatment of RDT-positive
(and RDT-negative) fevers in
children 0–4 years [28], applied to
uncomplicated malaria cases in all
age groups
LiST Households owning ≥1 ITNs or protected by IRS as measured
in the most recent national-representative household survey
(usually MIS, MICS or DHS)a
Children 0–4 years with a fever
treated within 48 h of fever onset
with an artemisinin-containing
compound i.e. ACT as measured
in the most recent national-
representative household survey
(usually MIS, MICS or DHS)a
Abbreviations: ACT Artemisinin-based Combination Therapy, DHS Demographic and Health Survey, DRC Democratic Republic of the Congo, ITN Insecticide-treated
mosquito net, IRS Indoor Residual Spraying, LiST Lives Saved Tool, MAP Malaria Atlas Project, MICS Multiple Indicator Cluster Survey, MIS Malaria Indicator Survey,
SSA sub-Saharan Africa, Swiss TPH Swiss Institute of Tropical and Public Health, PfPR Plasmodium falciparum parasite prevalence rate
aLiST uses the measured values for years in which surveys occurred, and applies linear interpolation between measured points. For years after the last survey in a
country, LiST assumes that coverage is constant
bPrecise annual coverages for each intervention, scenario, and model are shown in Additional file 1
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Discussion
The presented projections of impacts of ITNs and CMU
on malaria mortality from two models show how
Spectrum-Malaria usefully corroborates and complements
LiST, in projecting impacts of key malaria interventions
including their variation over time with some dynamic
transmission effects materializing from six years after
scale-up, variation by baseline endemicity and as a func-
tion of baseline coverage levels, and dynamic interactions
between interventions. Overall, Spectrum-Malaria broadly
supports the magnitude of mortality impacts of ITNs and
CMU projected by LiST [3] and several retrospective im-
pact evaluations [2, 29, 30] for falciparum-endemic Afri-
can settings. The similar proportional mortality
reductions over the first two years following scale-up of
ITNs from near-zero baselines to moderately higher cov-
erages are as expected, since both models were validated
on cluster-randomized ITN trials in moderate-to-high-en-
demic settings with a 2-year duration. The ITN-related
mortality reductions projected are also in line with
Fig. 1 Impacts over time, for ‘Coverage-standardized’ country variants of DRC and Zambia. Constant coverage as defined in Table 3 for year 2015,
Coverage-standardized variants of DRC and Zambia. For ITN + CMU combined (green lines), target coverages (for years 2016 and onward) are
98% ITN ownership in LiST or 70% ITN usage in Spectrum-Malaria, and 40% CMU coverage
Fig. 2 Deaths in 0–4 year-olds, relative to constant-coverage scenario, (left) 2020 and (right) 2025. Constant coverage as defined in Table 3 for
year 2015, Coverage-standardized variants of DRC and Zambia. For ITN + CMU combined (yellow bars), target coverages (for years 2016 and
onward) are 98% ITN ownership in LiST or 70% ITN usage in Spectrum-Malaria, and 40% CMU coverage
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Table 4 Relative under-5 malaria mortality levels after simultaneous scale-up of CMU and ITNs
Scale-up scenario LiST Spectrum-Malaria
DRC Zambia DRC Zambia
ITN 77% ownership or 51% usage; Uncomplicated Case Management 10%
(i.e. constant coverage scenario of Figs. 1, 2 and 3)
100% 100% 100% 100%
ITN 98% ownership or 70% usage (single intervention) 80% 80% 90% 88%
Uncomplicated Case Management 40% (single intervention) 67% 67% 59% 49%
ITN 98% ownership or 70% usage & Uncomplicated Case Management 40%
(two interventions concurrently)
53.8% 53.8% 54.7% 43.8%
Product of Relative mortality levels after ITN scale-up (to 98% ownership or
70% usage) alone, and after scale-up of Uncomplicated Case Management
(to 40%) alone
53.9% 53.8% 53.2% 42.8%
The results percentages reflect the mortality level at 2020 in the scale-up scenario, relative to the mortality level at 2020 in the scenario with coverages held
constant at 2015 levels. Each coverage scale-up was implemented as an immediate coverage increased from 2015 to 2016, and maintained over 2016–2030.
ITN ownership indicates coverage level projected in LiST; ITN usage indicates coverage level projected in Spectrum-Malaria
Fig. 3 Impacts of ITN scale-down from 2016, for ‘Coverage-standardized’ variants of (left) DRC and (right) Zambia. (top) LiST, malaria deaths and
(middle) Spectrum-Malaria, malaria deaths; (bottom): LiST and Spectrum-Malaria, Malaria mortality rate relative to the constant-coverage scenario.
Scale-down scenarios shown entailed a drop from 51% to 12.5% in ITN utilization in Spectrum-Malaria, or from 77% to 18% ITN ownership and/or
IRS sprayed in LiST
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magnitudes of mortality decline associated with the in-
creased malaria donor funding over the 2000s, which had
been allocated primarily to ITN distribution programs
and improved case management [31, 32].
In comparison, a recent assessment of impacts ex-
pected over 2015–2030 from scaling-up malaria control
according to the WHO’s Global Technical Strategy,
using the Imperial College London malaria transmission
model, projected a possible reduction in malaria
mortality rates of 40% (across all ages) from 2010 to
2030 across 80 countries with sustained stable malaria
transmission in 2010 [33]. This would seem to be a
smaller impact than projected by LiST and especially
Spectrum-Malaria for the combined scale-up of ITN and
CMU in DRC and Zambia (Fig. 2). Strict quantitative
comparison should rather be pursued country by country
and age group by age group, for standardized intervention
packages and coverage increments, as recently done with
OpenMalaria, the Imperial College London model and
two other dynamic models for the child health impacts of
RTS,S vaccination [34]. That comparison illustrated that
uncertainties about malaria pathogenesis as a function of
acquired immunity, and the resulting age distribution in
malaria burdens, especially in low-transmission settings,
leave a considerable margin of uncertainty about the mag-
nitude of (proportional and absolute) health impacts of
malaria control, and about effectiveness rankings among
interventions. In this context, the projection results that
we presented for DRC and Zambia in fact seem quite con-
sistent between LiST and Spectrum-Malaria.
Importantly, the Spectrum-Malaria projections suggest
that the gains expected from ongoing ITN scale-up to-
ward universal coverage —as targeted now by the WHO’s
Global Technical Strategy for Malaria 2016–2030 — may
be somewhat smaller than predicted by LiST, while the
potential impact of CMU may be larger. In drawing
national strategic plans for malaria control, program
planners should, however, consider the modelled ranking
of impacts alongside mapping of the cascades of services,
activities and inputs needed to achieve a given coverage
level and increase —which for ITNs (through vertical dis-
tribution campaigns) may be easier than for CMU (which
typically requires a broader health systems strengthening).
Tellingly, of the 663 million malaria cases averted in sub-
Saharan Africa due to malaria control interventions over
2000–2015, it was estimated that 69% were averted due to
use of ITNs, and only 21% due to ACT-based treatment,
and 10% due to IRS [2]. Spectrum-Malaria can support
comprehensive impact and cost-effectiveness evaluation
through its One Health Tool module, which links with im-
pacts projected through LiST and the Spectrum-Malaria
module.
The structural differences between Spectrum-Malaria
and LiST (Table 1) underlie several important differences
in impact results, besides different (generally larger) long-
term impacts compared to short-term population level
Fig. 4 Non-linearities in mortality impacts of ITNs and CMU, following scale-up or scale-down at 2016. The y-axes express the mortality level at
2020, in the scale-up or scale-down scenario, relative to the mortality level projected at 2020 under ‘constant’ coverages as shown in Figs. 1, 2
and 3: CMU coverage is kept constant at 10%, ITN household ownership at 77% (in LIST) and ITN usage at 51% (in Spectrum-Malaria); the mortality
level at these coverage levels are each displayed as 100%, so as to allow displaying both countries within the same chart despite their differing malaria
mortality levels
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impacts. First, Spectrum-Malaria projects proportionally
larger burden reductions for settings with lower baseline
burdens. This was evident in the current projections as
larger proportional mortality reductions for Zambia com-
pared to DRC, and it applies to other settings and other
malaria-related health outcomes as well, being a function
of statistical relationships driving impact projection in
Spectrum-Malaria, which include a negative coefficient
for PfPR, so that settings with higher PfPR will systematic-
ally have lesser proportional burden reductions for any
given coverage increase [13]. Of note, while this pattern
was illustrated here as a difference between Zambia and
DRC, the endemicity effect is modelled in Spectrum-
Malaria at the sub-national level (of Admin1 units, i.e. first
sub-national level), so that within Zambia, within DRC or
within any other country, the proportional health impacts
are larger in lower-endemic provinces or states than in
those with higher endemicity. This modelled pattern is
consistent with observations from ITN trials [17] and with
models of the dynamics induced by various malaria inter-
ventions [34–37]. In contrast, absolute health gains —in
terms of cases and deaths averted for a given coverage
increase— are generally larger for higher-endemic settings
(e.g. DRC more than Zambia), due to their larger baseline
burden compared to lower-endemic settings.
Second, more influentially, in Spectrum-Malaria the
incremental impacts for a given coverage percentage
increase saturate at higher coverages. LiST, in contrast,
by default calculates impacts fully linearly with coverage
increases throughout the 0–100% coverage range. And a
special option in LiST called ‘transmission herd effect’
allows users to even amplify impacts of ITN and/or IRS
protection by specifying proportions of children who are
themselves uncovered by ITN and/or IRS to still be pro-
tected from malaria – but there are no default assump-
tions for this effect, and the herd effect option cannot
model negative (saturating) effects of saturating ITN or
IRS coverage.
Third, in Spectrum-Malaria, the combined impact of
simultaneous scale-up of multiple interventions does not
necessarily equate the product of the individual interven-
tions’ proportional impacts (as in LiST), but this can be
less due to saturation effects, as shown for concurrent
ITN and CMU scale-up in DRC and Zambia (Figure 3). In
other settings, notably higher-endemic settings with lower
baseline and target coverages (not shown), Spectrum-
Malaria projects synergy between interventions, whereby
combinations of interventions reduce transmission and
endemicity more strongly, and the incremental effect of
additional interventions then amplifies the overall effect be-
yond the contributions of single interventions [13]. These
saturation and synergic effects reflect the dynamics of mal-
aria control, as simulated in OpenMalaria [38] and emu-
lated through Spectrum’s statistical impact functions [13].
Fourth (less relevant to the child health perspective
and comparison with LiST, but important for overall in-
fectious disease and health sector planning) Spectrum-
Malaria projects important impacts of malaria control
on morbidity and mortality in children above five years
and adults. These older age groups have much lower
shares in malaria morbidity and mortality burdens,
which malaria intervention coverage scale-up would re-
duce by near-similar proportions as shown here for chil-
dren under-5 —but with some rebounds in longer-term
reflecting declining acquired immunity in cohorts of
people benefiting from enhanced malaria protection
[13]. As a result, Spectrum-Malaria, like the dynamic
transmission models that informed it, predicts that en-
hanced malaria control will progressively shift malaria
burden to older ages and result in a more homogeneous
distribution of malaria over age [39] (as already seen in
lower-endemic settings outside of Africa), heightening
the importance of including over-fives in impact evalu-
ation and strategic program planning.
Finally, LiST remains unique in examining the impact of
malaria interventions within the context of all causes of
child mortality. Impacts of malaria interventions on abso-
lute numbers of deaths are influenced by interventions
that affect those other causes, as they affect the number of
children exposed to malaria mortality. This enables com-
parisons of malaria interventions with other child survival
interventions and focuses attention on opportunities cur-
rently being missed for reducing child mortality, by target-
ing the major causes of child deaths for which effective
interventions exist but are not yet implemented to scale.
Limitations
Limitations of the Spectrum-Malaria and LiST tools,
that influence the projection results compared here, have
been discussed elsewhere [10–12]. These include that
country under-5 malaria mortality data used for the
2015 baseline were themselves model-based and subject
to uncertainty and annual re-estimation [1, 40–42].
Further in terms of data inputs, coverage definitions and
the assumed baseline and target levels were not necessar-
ily comparable between both models. For ITNs, the
relationship between household ownership of ≥1 ITNs
(used in LiST) and usage (used by Spectrum-Malaria) is
well-characterized by recent multi-country analyses, but
this may change as coverage increases and over-allocation
to households with already enough ITNs, at the expense
of less accessible households who still lack ITNs,
increases.
For CMU, both models used coverage estimates for
children under-5 years, but LiST assumed no treatment
in older age groups, and considered only treatments
within 48 h of onset of fever, while the CMU coverages
used by Spectrum-Malaria ignored timeliness of
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treatment but focused on fevers with RDT-confirmed
parasitemia [28]. It is not clear how the two sets of
coverage estimates relate, and this uncertainty com-
pounds large uncertainty in effectiveness of CMU.
Malaria treatments in older age groups modeled in
Spectrum-Malaria (at the same coverage as for
children under-5) but not in LiST, including their
dynamic transmission-reducing effects over time, ex-
plains why Spectrum-Malaria projected larger long-term
impacts of CMU —especially in low-endemic Zambia
where high coverage of CMU might, in some of the
lower-endemic areas within the country, feasibly drive
malaria transmission down to pre-elimination levels. It is
hard to say which model is more realistic here, lacking
cluster-randomized trials of population-level CMU im-
pacts. The range of impacts between the two models may
well capture the real typical magnitude —as well as the
uncertainty or variation— in CMU impacts. A more com-
prehensive, refined comparison between both models of
health impacts and cost-effectiveness of CMU should fur-
thermore take into account the required volumes of treat-
ments (across all ages) and other program inputs involved
in the respective CMU scale-ups projected. Both models
will likely benefit from aligning CMU coverage baseline
data, building on progressively improving estimates of ef-
fective CMU coverage for parasitologically confirmed mal-
aria to replace current coverage estimates based on child
fevers from any cause, that also take into account antimal-
arial drug availability, quality, patient adherence and com-
pliance, timeliness, caretakers’ recall of treatment histories
in household surveys [43], and sub-national geographical
variation in these determinants of CMU coverage [2, 28,
44]. Such forthcoming refined CMU coverage estimates
will also be used for ecological, statistical assessments of
historic CMU impacts over space and time in Africa (as
recently done for ITNs, IRS and ACT access [2]), which
may provide an opportunity to triangulate and validate
CMU effectiveness assumptions.
For ITNs, while effectiveness has been fairly precisely
estimated for scale-up as occurred over the past decade,
and both LiST and Spectrum-Malaria fitted to that, the
incremental impacts of ongoing further ITN scale-up
may saturate with increasing coverage, which was cap-
tured in Spectrum-Malaria but not in LiST. Finally, ITN
and IRS impacts will diminish as insecticide resistance
develops and spreads. Insecticide resistance was not cap-
tured in either model, but should be added as an impact
modifier when good-quality standardized data on WHO-
recommended resistance indicators become available at
country and sub-national resolution [45]. Similarly,
CMU effectiveness may be lower in settings with para-
sitological resistance against the locally used antimalarial
drugs [1], an effect modifier not yet captured in either
model’s impact assumptions.
Implications for program planning
Going forward, to optimally use LiST and Spectrum-
Malaria for program and health sector planning, we rec-
ommend that program planners use both models in
complement. Spectrum-Malaria probably gives the best
comprehensive impact projection for ITNs, IRS and
CMU —including dynamic transmission effects as they
evolve over time and over successive phases of malaria
control, and vary with baseline epidemic conditions of
each settings. Spectrum-Malaria adds to the arsenal of
malaria interventions projected with seasonal malaria
chemoprophylaxis (recommended in countries and areas
with strongly seasonal malaria, mainly in Western and
Sahelian Africa) and with improved management of se-
vere malaria cases. LiST, but not Spectrum-Malaria,
models the impact of Intermittent Preventive anti-
malarial Therapy for pregnant women (IPTp), which
benefits women receiving this intervention, and their in-
fants directly. While the population-level impacts of
IPTp (which is not known to produce onward dynamic
transmission effects at population level) are small com-
pared to transmission-reducing interventions that are
the focus of Spectrum-Malaria, IPTp is an essential
component of maternal, neonatal and child health care
packages, that requires evaluation in the LiST context
considering maternal, neonatal and child health out-
comes specifically. And only LiST models malaria mor-
tality in the context of other-cause under-five mortality,
allowing validation against field program data that
typically measure and monitoring all-cause under-five
mortality without ascertainment of causes [46]. While
Spectrum-Malaria primarily focuses on modeling dy-
namic interactions among malaria interventions, LiST
provides a framework that more easily allows evaluations
across a wider set of causes of child deaths with their
possible interactions. For example, recent evidence sug-
gests a link between sub-optimal breastfeeding and in-
creased risk of malaria mortality in children under the
age of six [47]. Such effects can be captured using the
LiST approach, but would not be straightforward to ac-
count for in Spectrum-Malaria.
To facilitate the complementary use of LiST and
Spectrum-Malaria, modelers should align the baseline
country data included in both models, i.e. malaria mor-
tality rates, populations living at risk of Plasmodium
falciparum transmission, and recent coverage levels and
trends of ITNs, IRS and CMU. To do cost comparison
with both models jointly, also their assumed proportions
of population living at risk of malaria should be aligned,
since these determine the population in need of malaria
interventions. Comparison and alignment may be fur-
ther facilitated if Spectrum-Malaria would compute and
display health impacts for pregnant women, as a distinct
sub-group of adults. A future way to incorporate in LiST
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the non-linearity in coverage-impact relationships, and
saturation and synergy across malaria interventions as
illustrated by Spectrum-Malaria, would be for LiST to
extend the herd effect c.q. transmission interruption op-
tion, that LiST currently allows for modelling of ITNs/
IRS but not yet for malaria treatment.
Conclusion
In conclusion, Spectrum-Malaria aligns with LiST in the
proportional under-5 mortality reduction following ITN
scale-up from low (0–20%) to current/high ITN cover-
age, as expected given that both models were fitted to
the results of the same ITN trials. However, for scale-up
from current intermediate coverage levels to universal
coverage, Spectrum-Malaria suggests that important coun-
try variations and saturation effects in impacts are expected
that are not evident from LiST. For CMU, Spectrum-
Malaria predicts somewhat larger proportional impacts
than LiST, which may reflect real long-term dynamic
effects, although the precise impact of CMU remains
uncertain lacking a controlled-trial-based gold standard.
Strategic planners in malaria-endemic African countries
can use the two models in a complementary way, within
the Spectrum platform, to inform various malaria and
health sector strategic planning purposes, including those
focusing on population level health beyond child mortality.
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